The Final Frontier of Drug Delivery: Navigating the Blood-Brain Barrier
The next generation of CNS therapies will depend on crossing the blood-brain barrier safely, selectively, and at therapeutic scale.
Recuro Health, a digital health solutions startup aiming to shift U.S. healthcare from reactive to proactive care, has closed a $47 M Series B financing round led by ARCH Venture Partners, Flippen Group, GPG Ventures, 4D Capital and others
Use of Funds
The new capital will be used to expand its “Digital Medical Home” model—offering virtual primary care, behavioral health, at‑home lab testing and genomics—integrating advanced diagnostics and targeted cancer-screening tools to support proactive clinical workflows
Leadership Commentary
Michael Gorton, CEO and founder, stated:
“The continued support of our investors is a clear sign of their confidence in our mission… committed to building upon the success of our Digital Medical Home and continuing to advance the next generation of digital care services.”
Robert Nelsen of ARCH added that Recuro is “best of breed in the intersection of science, diagnostics and digital health,” and praised its ability to respond to market shifts and close gaps in care
Scaling & Reach
Founded in 2021, Recuro’s services—covering virtual primary and urgent care, behavioral health, at-home lab testing and genomics—are now used by millions nationwide
Future Vision
The company aims to integrate data analytics, care navigation, quality services and guided referrals into a unified virtual-first platform, striving to reduce costs, improve outcomes, and replace fragmented PDF-based records with real-time patient data
Read more
All Posts
All Posts
Tiny Molecules, Tinier Incentives: How the IRA Rewrote the Small-Molecule Economy
Even the strongest science does not guarantee an investable asset. Here, we discuss how to align early-stage discovery programs for small molecules with investor expectations in a complex biotech funding environment.
Ready to Transform Healthcare?
Join us in building the future of medicine through innovative technology and biology convergence